{"DataElement":{"publicId":"7115526","version":"1","preferredName":"Tumor Mass Histologic Low Grade Glioma WHO Classification of Tumors Grade","preferredDefinition":"The World Health Organization (WHO) classification of grade I or grade II glioma tumors based primarily on histologic findings.","longName":"7113170v1.0:7113078v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7113170","version":"1","preferredName":"Tumor Mass Histologic Grade","preferredDefinition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells._The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","longName":"4976411v1.0:2427327v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"4976411","version":"1","preferredName":"Tumor Mass","preferredDefinition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells.","longName":"C98275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Mass","conceptCode":"C98275","definition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DC5FA96-6845-8A34-E050-BB89AD4344BC","latestVersionIndicator":"Yes","beginDate":"2015-08-20","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-08-20","modifiedBy":"ONEDATA","dateModified":"2015-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2427327","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05116195-EBA8-7341-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A7A53E6-D421-653E-E053-F662850AD4E6","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeDescription":"5/14/20 jk Released per SME (NGM) review and approval email. 12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7113078","version":"1","preferredName":"Low Grade Glioma WHO Classification of Tumors Grade","preferredDefinition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma._A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings._A position on a scale of intensity or amount or quality.","longName":"7113078v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"WHO Grade II","valueDescription":"WHO Central Nervous System Grade II","ValueMeaning":{"publicId":"2581532","version":"1","preferredName":"WHO Central Nervous System Grade II","longName":"2581532","preferredDefinition":"A suffix denoting the second person having the same complete name (first, middle, and family names).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 2","conceptCode":"C62395","definition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0B89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"LEEB","dateModified":"2008-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A799551-9102-5A66-E053-F662850AE5D0","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"},{"value":"WHO Grade III","valueDescription":"WHO Central Nervous System Grade III","ValueMeaning":{"publicId":"2581533","version":"1","preferredName":"WHO Central Nervous System Grade III","longName":"2581533","preferredDefinition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 3","conceptCode":"C62396","definition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0B8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"LEEB","dateModified":"2008-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A799551-90ED-5A66-E053-F662850AE5D0","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008526","version":"1","preferredName":"Anatomic Sites","preferredDefinition":"locations or structures in the human body.","longName":"ANAT_SITES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ED0F8B-4D91-332D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7113077","version":"1","preferredName":"Low Grade Glioma WHO Classification of Tumors Grade","preferredDefinition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.:A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.:A position on a scale of intensity or amount or quality.","longName":"C132067:C113304:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade Glioma","conceptCode":"C132067","definition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"WHO Classification of Tumors","conceptCode":"C113304","definition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A799551-90BA-5A66-E053-F662850AE5D0","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A799551-90CB-5A66-E053-F662850AE5D0","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeDescription":"5/14/20 jk Released per SME (NGM) review and approval email.  12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6779545","version":"1","longName":"LGG Local Pathology","context":"OCCPR"},{"publicId":"6779546","version":"1","longName":"LGG Pathology Review","context":"OCCPR"},{"publicId":"6601275","version":"1","longName":"Brain","context":"OCCPR"},{"publicId":"6779544","version":"1","longName":"LGG Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Histologic Grade","type":"Preferred Question Text","description":"Histologic Grade","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB2B392-BAAA-7E59-E053-F662850AAFB1","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeDescription":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/27/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}